Memphis scientists instrumental in new, landmark COVID drug
‘This is the last piece of the puzzle’
Certified Medical Assistant Jaimee Lapham (left) administers a COVID-19 test on Jan. 11, 2022, at the drive-thru testing site at Collierville High School. COVID is still killing 450 Americans a day, about one 9/11 every four days. (Mark Weber/The Daily Memphian file)
The next possible landmark COVID drug is so rich in Memphis DNA that if approved by the FDA, patent royalty checks will immediately flow to town. Plus, it’s in capsule form, taken once a day for 21 days. It does not need to be refrigerated and can be shipped easily and inexpensively around the world.
Topics
UTHSC Mitchell Steiner GTx COVID-19 sabizabulin Subscriber OnlyThank you for supporting local journalism.
Subscribers to The Daily Memphian help fund our not-for-profit newsroom of nearly 40 local journalists plus more than 20 freelancers, all of whom work around the clock to cover the issues impacting our community. Subscriptions - and donations - also help fund our community access programs which provide free access to K-12 schools, community organizations, and more. Thank you for making our work possible.
Jane Roberts
Longtime journalist Jane Roberts is a Minnesotan by birth and a Memphian by choice. She's lived and reported in the city more than two decades. She covers business news and features for The Daily Memphian.
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.